Cargando…
Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice
Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approaches, both of which aim to target and enhance the c...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196021/ https://www.ncbi.nlm.nih.gov/pubmed/37213494 http://dx.doi.org/10.3389/fmicb.2023.1173061 |
_version_ | 1785044254317346816 |
---|---|
author | Qi, Ruoyao Cao, Jiali Wu, Yangtao Lei, Xing He, Jinhang Zhang, Liang Fu, Rao Chen, Feng Wang, Yingbin Zhang, Tianying Xia, Ningshao Yuan, Quan |
author_facet | Qi, Ruoyao Cao, Jiali Wu, Yangtao Lei, Xing He, Jinhang Zhang, Liang Fu, Rao Chen, Feng Wang, Yingbin Zhang, Tianying Xia, Ningshao Yuan, Quan |
author_sort | Qi, Ruoyao |
collection | PubMed |
description | Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approaches, both of which aim to target and enhance the clearance of HBsAg and HBV-DNA. The first approach involves the use of antibodies to continuously suppress HBsAg, followed by the administration of a therapeutic vaccine in a sequential manner. This approach results in better therapeutic outcomes compared to the use of these treatments individually. The second approach involves combining antibodies with ETV, which effectively overcomes the limitations of ETV in suppressing HBsAg. Thus, the combination of therapeutic antibodies, therapeutic vaccines, and other existing drugs is a promising strategy for the development of novel strategies to treat hepatitis B. |
format | Online Article Text |
id | pubmed-10196021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101960212023-05-20 Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice Qi, Ruoyao Cao, Jiali Wu, Yangtao Lei, Xing He, Jinhang Zhang, Liang Fu, Rao Chen, Feng Wang, Yingbin Zhang, Tianying Xia, Ningshao Yuan, Quan Front Microbiol Microbiology Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approaches, both of which aim to target and enhance the clearance of HBsAg and HBV-DNA. The first approach involves the use of antibodies to continuously suppress HBsAg, followed by the administration of a therapeutic vaccine in a sequential manner. This approach results in better therapeutic outcomes compared to the use of these treatments individually. The second approach involves combining antibodies with ETV, which effectively overcomes the limitations of ETV in suppressing HBsAg. Thus, the combination of therapeutic antibodies, therapeutic vaccines, and other existing drugs is a promising strategy for the development of novel strategies to treat hepatitis B. Frontiers Media S.A. 2023-05-05 /pmc/articles/PMC10196021/ /pubmed/37213494 http://dx.doi.org/10.3389/fmicb.2023.1173061 Text en Copyright © 2023 Qi, Cao, Wu, Lei, He, Zhang, Fu, Chen, Wang, Zhang, Xia and Yuan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Qi, Ruoyao Cao, Jiali Wu, Yangtao Lei, Xing He, Jinhang Zhang, Liang Fu, Rao Chen, Feng Wang, Yingbin Zhang, Tianying Xia, Ningshao Yuan, Quan Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice |
title | Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice |
title_full | Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice |
title_fullStr | Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice |
title_full_unstemmed | Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice |
title_short | Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice |
title_sort | combination therapy of therapeutic antibody and vaccine or entecavir in hbv carrier mice |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196021/ https://www.ncbi.nlm.nih.gov/pubmed/37213494 http://dx.doi.org/10.3389/fmicb.2023.1173061 |
work_keys_str_mv | AT qiruoyao combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT caojiali combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT wuyangtao combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT leixing combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT hejinhang combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT zhangliang combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT furao combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT chenfeng combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT wangyingbin combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT zhangtianying combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT xianingshao combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice AT yuanquan combinationtherapyoftherapeuticantibodyandvaccineorentecavirinhbvcarriermice |